Benzinga | Jul 29, 2021 07:19AM EDT

Intercept Pharmaceuticals Q2 EPS $(0.33) Beats $(1.21) Estimate, Sales $96.58M Beat $82.95M Estimate

Intercept Pharmaceuticals (NASDAQ:ICPT) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(1.21) by 72.73 percent. This is a 82.81 percent increase over losses of $(1.92) per share from the same period last year. The company reported quarterly sales of $96.58 million which beat the analyst consensus estimate of $82.95 million by 16.43 percent. This is a 25.02 percent increase over sales of $77.25 million the same period last year.